KRYS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KRYS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Krystal Biotech's Cost of Goods Sold for the three months ended in Mar. 2024 was $2.42 Mil. Krystal Biotech's Average Total Inventories for the quarter that ended in Mar. 2024 was $9.01 Mil. Krystal Biotech's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.27.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Krystal Biotech's Days Inventory for the three months ended in Mar. 2024 was 339.91.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Krystal Biotech's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.20.
The historical data trend for Krystal Biotech's Inventory Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Inventory Turnover | Get a 7-Day Free Trial | - | - | - | - | 0.44 |
Krystal Biotech Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Inventory Turnover | Get a 7-Day Free Trial | - | - | 0.04 | 0.47 | 0.27 |
Krystal Biotech's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as
Inventory Turnover (A: Dec. 2023 ) | |||||||
= | Cost of Goods Sold | / | Average Total Inventories | ||||
= | Cost of Goods Sold (A: Dec. 2023 ) | / ( | (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) |
= | 3.094 | / ( | (0 | + | 6.985) | / | 1 ) |
= | 3.094 | / | 6.985 | ||||
= | 0.44 |
Krystal Biotech's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as
Inventory Turnover (Q: Mar. 2024 ) | |||||||
= | Cost of Goods Sold | / | Average Total Inventories | ||||
= | Cost of Goods Sold (Q: Mar. 2024 ) | / ( | (Total Inventories (Q: Dec. 2023 ) | + | Total Inventories (Q: Mar. 2024 )) | / | count ) |
= | 2.419 | / ( | (6.985 | + | 11.037) | / | 2 ) |
= | 2.419 | / | 9.011 | ||||
= | 0.27 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech (NAS:KRYS) Inventory Turnover Explanation
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Krystal Biotech's Days Inventory for the three months ended in Mar. 2024 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Mar. 2024 ) | / | Cost of Goods Sold (Q: Mar. 2024 ) | * | Days in Period |
= | 9.011 | / | 2.419 | * | 365 / 4 | |
= | 339.91 |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Krystal Biotech's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Mar. 2024 ) | / | Revenue (Q: Mar. 2024 ) |
= | 9.011 | / | 45.25 | |
= | 0.20 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.
Thank you for viewing the detailed overview of Krystal Biotech's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Krish S Krishnan | director, 10 percent owner, officer: President and CEO | 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Suma Krishnan | director, 10 percent owner, officer: Chief Operating Officer | 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Catherine Mazzacco | director | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Daniel Janney | director | PO BOX 7414, JACKSON WY 83002 |
Andrew C. Orth | officer: Chief Commercial Officer | 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Kathryn Romano | officer: Chief Accounting Officer | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Dino A Rossi | director | 61 WATROO POINT, DANIEL ISLAND SC 29492 |
Everett Rand Sutherland | director | 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
Christopher Mason | director | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Jing L. Marantz | director | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Julian S Gangolli | director | 4955 BASELINE AVENUE, SANTA YNEZ CA 93460 |
Jennifer Chien | officer: Chief Commercial Officer | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Antony A Riley | officer: Chief Financial Officer | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538 |
R Douglas Norby | director | C/O MAGNACHIP SEMICONDUCTOR, INC., 20400 STEVENS CREEK BOULEVARD, SUITE 370, CUPERTINO CA 95014 |
Sun Pharma (netherlands) B.v. | 10 percent owner | POLARISAVENUE 87, 2132 JH HOOFDDORP P7 00000 |
From GuruFocus
By Marketwired • 07-26-2023
By GuruFocus Research • 09-13-2023
By Marketwired • 07-03-2023
By sperokesalga sperokesalga • 05-22-2023
By Value_Insider Value_Insider • 11-23-2022
By Value_Insider Value_Insider • 12-01-2022
By Value_Insider Value_Insider • 12-05-2022
By GuruFocus Research GuruFocus Editor • 01-04-2023
By Marketwired • 10-30-2023
By Marketwired • 09-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.